Table 3.
Example of drugs shown (or suspected) to aggravate pre-existing metabolic dysfunction-associated fatty liver disease (MAFLD), or to favour the transition of pre-existing fatty liver to nonalcoholic steatohepatitis (NASH). Further information is provided in previous articles [[38], [39], [40], [41], [42], [43]].
| Drug | Therapeutic class |
|---|---|
| Androgenic steroids Benzbromarone Corticosteroids Irinotecan Methotrexate NRTIs1 (e.g. stavudine, didanosine) Pentoxifylline Phenobarbital Protease inhibitors (e.g. lopinavir, ritonavir) Raloxifene Rosiglitazone Tamoxifen Tetracycline |
Anabolic Uricosuric Anti-inflammatory Anticancer Immunosuppressant, antimetabolite Antiretroviral Hemorrheologic agent, anti-TNF-α1 Antiepileptic Antiretroviral Anti-osteoporotic Antidiabetic (PPARγ1 agonist) Anticancer Antibiotic |
1
Abbreviations: NRTI, nucleoside reverse transcriptase inhibitor; PPARγ, peroxisome proliferator activated receptor gamma; TNF-α, tumour necrosis factor-alpha.